Saturday, 5 September 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 3, 2025

Toymaker Gears Up for Supreme Court Fight Over Trump’s Tariffs

View original at finance.yahoo.com
Toymaker Gears Up for Supreme Court Fight Over Trump’s Tariffs (Bloomberg) — Ask Rick Woldenberg why he’s challenging President Donald Trump’s tariffs at the US Supreme Court, and he might mention a furry unicorn yoga ball…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Expected tariff bill for 2025 is $20-30 million, far above last year's $2.3 million

    80% confidence
  • The administration has backup plans and the president's trade team is working diligently on contingency plans if tariffs are struck down

    80% confidence
  • To the president, these cases present a stark choice: With tariffs, we are a rich nation; without tariffs, we are a poor nation

    80% confidence
  • When taken all together, Trump's tariffs clearly are a net benefit for the country and for American workers

    80% confidence
  • The president has no power to impose taxes on American citizens without the authorization of Congress, and tariffs are taxes on American importers

    80% confidence
  • He expects to incur millions of dollars in legal bills even after accepting contributions from unnamed outsiders

    80% confidence
  • He won't take help from non-Americans or anyone with political affiliations and is not a front for anyone else

    80% confidence
  • THE MOST IMPORTANT CASE EVER IS IN THE UNITED STATES SUPREME COURT

    80% confidence
  • The companies are like itinerant refugees in how they make products, going from jurisdiction to jurisdiction, and no matter what they guess, it seems wrong

    80% confidence
  • The tariffs have already helped secure multiple trade deals that level the playing field for American workers and industries and are securing trillions in investments to make and hire in America

    80% confidence
  • Tariffs will raise revenue, open up foreign markets, and bring manufacturing jobs back to the US

    80% confidence
  • We paid a $50,000 penalty for the BubblePlush shipment arriving six hours late before the 50% India tariff took effect

    80% confidence
  • He doesn't personally tell himself he's taking on Donald Trump, but advocating for himself, people who depend on the company, and issues important to every American

    80% confidence
  • He was shocked that those with much more power and money did not step up to challenge the tariffs

    80% confidence
  • Manufacturing overseas reflects longstanding industry practice due to lower labor costs abroad, not because companies don't invest in America

    80% confidence
  • He doesn't think he will attend oral arguments, reversing himself after suggesting he might watch proceedings in person, to avoid deflecting from the importance of the decision

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com